Assessment of Plasma and Cerebrospinal Fluid Biomarkers in Different Stages of Alzheimer’s Disease and Frontotemporal Dementia
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24021226 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Lourdes Álvarez-Sánchez und 6 weiteren Autor:innen. Beteiligte Einrichtung: Alzheimer Disease Research Group, Instituto de Investigación Sanitaria La Fe, 46026 Valencia, Spain. Hauptthemen laut MEDLINE: Alzheimer Disease, Frontotemporal Dementia, Frontotemporal Lobar Degeneration, Pick Disease of the Brain. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III, European Regional Development Fund.
Themen: Demenz
Abstract (Originalsprache)
Alzheimer’s disease (AD) is the primary type of dementia, followed by frontotemporal lobar degeneration (FTLD). They share some clinical characteristics, mainly at the early stages. So, the identification of early, specific, and minimally invasive biomarkers is required. In this study, some plasma biomarkers (Amyloid β42, p-Tau181, t-Tau, neurofilament light (NfL), TAR DNA-binding protein 43 (TDP-43)) were determined by single molecule array technology (SIMOA®) in control subjects (n = 22), mild cognitive impairment due to AD (MCI-AD, n = 33), mild dementia due to AD (n = 12), and FTLD (n = 11) patients. The correlations between plasma and cerebrospinal fluid (CSF) levels and the accuracy of plasma biomarkers for AD early diagnosis and discriminating from FTLD were analyzed. As result, plasma p-Tau181 and NfL levels correlated with the corresponding CSF levels. Additionally, plasma p-Tau181 showed good accuracy for distinguishing between the controls and AD, as well as discriminating between AD and FTLD. Moreover, plasma NfL could discriminate dementia-AD vs. controls, FTLD vs. controls, and MCI-AD vs. dementia-AD. Therefore, the determination of these biomarkers in plasma is potentially helpful in AD spectrum diagnosis, but also discriminating from FTLD. In addition, the accessibility of these potential early and specific biomarkers may be useful for AD screening protocols in the future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Alzheimer Disease Research Group, Instituto de Investigación Sanitaria La Fe, 46026 Valencia, Spain.
- Faculty of Mathematical Sciences, University of Valencia, 46100 Burjassot-Valencia, Spain.
- Division of Neurology, University and Polytechnic Hospital La Fe, 46026 Valencia, Spain.
ORCID-Profile: Lourdes Álvarez-Sánchez, Laura Ferré-González, Consuelo Cháfer-Pericás
Förderung
- Instituto de Salud Carlos III
- European Regional Development Fund
Zitieren
APA
Álvarez-Sánchez, L., Peña-Bautista, C., Ferré-González, L., Balaguer, A., Baquero, M., Casanova-Estruch, B., & Cháfer-Pericás, C. (2023). Assessment of Plasma and Cerebrospinal Fluid Biomarkers in Different Stages of Alzheimer’s Disease and Frontotemporal Dementia. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24021226
Vancouver
Álvarez-Sánchez L, Peña-Bautista C, Ferré-González L, Balaguer A, Baquero M, Casanova-Estruch B, et al. Assessment of Plasma and Cerebrospinal Fluid Biomarkers in Different Stages of Alzheimer’s Disease and Frontotemporal Dementia. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24021226
BibTeX
@article{lvarezSnchez2023,
author = {Álvarez-Sánchez, Lourdes and Peña-Bautista, Carmen and Ferré-González, Laura and Balaguer, Angel and Baquero, Miguel and Casanova-Estruch, Bonaventura and Cháfer-Pericás, Consuelo},
title = {Assessment of Plasma and Cerebrospinal Fluid Biomarkers in Different Stages of Alzheimer’s Disease and Frontotemporal Dementia},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24021226}
}
EUVIMED